Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J1GR
|
|||
| Former ID |
DCL000359
|
|||
| Drug Name |
CP-868596
|
|||
| Synonyms |
Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Gastrointestinal cancer [ICD-11: 2C11] | Phase 3 | [1], [2] | |
| Gastrointestinal stromal tumour [ICD-11: 2B5B] | Phase 3 | [3] | ||
| Acute myelogenous leukaemia [ICD-11: 2A41; ICD-10: C92.2] | Phase 2 | [4] | ||
| Acute myeloid leukaemia [ICD-11: 2A60] | Phase 2 | [3] | ||
| Malignant glioma [ICD-11: 2A00.0; ICD-9: 191] | Phase 1 | [4] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Pfizer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H29N5O2
|
|||
| Canonical SMILES |
CC1(COC1)COC2=CC3=C(C=C2)N(C=N3)C4=NC5=C(C=CC=C5N6CCC(CC6)N)C=C4
|
|||
| InChI |
1S/C26H29N5O2/c1-26(14-32-15-26)16-33-20-6-7-22-21(13-20)28-17-31(22)24-8-5-18-3-2-4-23(25(18)29-24)30-11-9-19(27)10-12-30/h2-8,13,17,19H,9-12,14-16,27H2,1H3
|
|||
| InChIKey |
DYNHJHQFHQTFTP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 670220-88-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
15379617, 22724199, 33999151, 78995356, 135267953, 135349234, 135626820, 136340262, 136349573, 136367704, 136920312, 137263558, 139541679, 144115852, 152258467, 160647302, 160681954, 162011433, 162038138, 162202696, 164838602, 172918813, 174006528, 174530261, 184828151, 198943954, 223366211, 223400256, 223705033, 223921696, 228815749, 247785884, 252110181, 252215199, 252451666
|
|||
| ChEBI ID |
CHEBI:145365
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7882). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015430) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 5 | The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.Invest New Drugs.2015 Apr;33(2):300-9. | |||
| REF 6 | Crenolanib, a PDGFR inhibitor, suppresses lung cancer cell proliferation and inhibits tumor growth in vivo.Onco Targets Ther.2014 Sep 26;7:1761-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.